Validation of a Capillary Electrophoresis Method for Analyzing Chlorphenamine Maleate-Based Drugs Using the Accuracy Profile Approach

This study aimed at validating an analytical method, using the accuracy profile approach, for the assay of chlorphenamine maleate by capillary electrophoresis. The validation was done using concentrations ranging between 75% and 125% of the target concentration of 600 mg/ml. Validation standards were prepared separately in triplicate for each series. Studied validation criteria were selectivity, linearity, trueness, precision (repeatability and intermediate precision), accuracy and limits of detection and quantification. The method was selective, with recoveries ranging between 99.55% and 99.84%. The relative standard deviations of repeatability and intermediate precision were <5%. The accuracy profile confirmed the performance of the assay method between 75% and 100% of the target concentration of 600 mg/ml. The detection and quantification limits were 5 mg/l and 15 mg/l respectively. This ecological and economical method was applied to identify and quantify chlorphenamine maleate in 3 samples of chlorphenamine maleate-based drugs provided by the Senegalese National Medicines Control Laboratory. All analyzed samples were in accordance with official standards.

Effects of tanshinone Ⅱ sodium sulfonate plus cinepazide maleate on the hemorrheologic indexes and blood lipids in patients with acute cerebral infarction

BACKGROUND： The severity of cerebral infarction is associated with the increase of blood viscosity caused by hyperfibrinogenemia and hyperlipidemia, etc. Thus it has become one of the target for treating cerebral infarction to decrease blood viscosity by integrated Chinese and western medicine. OBJECTIVE： To investigate the influence and clinical therapeutic effects of cinepazide maleate combined with tanshinone Ⅱ A sodium sulfonate on the hemorrheologic indexes and blood lipids of patients with acute cerebral infarction, and compare the results with those of simple cinepazide maleate treatment. DESIGN： A non-randomized case-controlled observation. SETTINGS： Hebei North University; the Second Affiliated Hospitals of Hebei North University; the Third Affiliated Hospitals of Hebei North University, PARTICIPANTS： Eighty-six inpatients with cerebral infarction were selected from the infirmary, the Second and Third Affiliated Hospitals of Hebei North University from September 2004 to October 2006. They were all diagnosed to have acute cerebral infarction by CT or MRI, and accorded with the diagnostic standards for acute cerebral infarction set by the Fourth National Academic Meeting for Cerebrovascular Disease in 1995. Meanwhile, 40 teachers and medical staff of voluntary physical examinees were selected as the control group. Informed contents were obtained from all the patients and their relatives. METHODS： The patients were divided into combined treatment group （n=43） and simple treatment group （n=3）. In the combined treatment group, the patients were administrated with 160 mg cinepazide maleate injection （Beijing Four-ring Pharmaceutical, Co.,Ltd, No. H200220125; 80 mg/2 mL） added in 5% glucose, and 40 mg tanshinone Ⅱ sodium sulfonate （Shanghai No.1 Biochemical ＆ Pharmaceutical Co.,Ltd., No. H31022558, 10 mg/2 mL） added in 250 mL normal saline. In the simple treatment group, the patients were only administrated with cinepazide maleate 320 mg added in 5% glucose or 250 mL normal saline. They were treated for 1 or 2 courses, once a day, and 14 days as a course. The patients were detected before treatment and at 14 and 28 days after treatment respectively. ① Determination of hemorrheologic indexes： Whole blood viscosity was determined with LBY-N6B automatic hemorrheologic meter; Plasma viscosity with LBY-F200B automatic plasma viscosity meter; Volume of fibrinogen was determined by the method of 12.5% sodium nitrate depositing biuret reaction. ② Determination of blood lipids： The serum levels of total cholesterol （TC）, triglyceride （TG）, low density lipoprotein cholesterol （LDL-C） and high density lipoprotein cholesterol （HDL-C） were determined. ③ Severity of neurological deficit： The total score of neurological deficit score （NDS） ranged from 0 to 45 points, 0 - 15 points was taken as mild, 16 - 30 points as moderate and 31 - 45 points as severe.④ Evaluation of curative effects： Generally cured： NDS decreased by 91% - 100%, and disabled severity of grade 0; Significantly improved： NDS decreased by 46% - 90%, and disabled severity of grades 1 - 3; Improved： NDS decreased by 18% - 45%; No change： NDS decreased by less than 18%; Aggravated： NDS increased by more than 18%. Generally cured and significant improved were taken as significant effect. ⑤ The adverse events and side effects after medication were observed. MAIN OUTCOME MEASURES： ① Results of hemorrheologic indexes and blood lipids; ② NDS results in the combined treatment group and simple treatment group; ③ Therapeutic effects and adverse events. RESULTS： All the 86 patients with cerebral infarction and 40 healthy controls were involved in the analysis of results. ① Results of hemorrheologic indexes and blood lipids： The hemorrheologic indexes and blood lipids before treatment were manifested as abnormalities to different extents in both the combined treatment group and simple treatment group; The hemorrheologic indexes after treatment were obviously improved in both groups. But the hemorrheologic indexes were improved more obviously in the combined treatment group as compared with those in the simple treatment group （P 〈 0.05）; The levels of TC, TG and LDL-C after treatment in the combined treatment group were obviously lowered （P 〈 0.05）, whereas those in the simple treatment group were not significantly changed （P 〉 0.05）. ② NDS results： The NDS scores at 14 and 28 days after treatment in the combined treatment group [（6.23±2.34）, （4.27± 1.83） points] were obviously lower than those in the simple treatment group [（8.76±3.41）, （6.65±2.49） points, P 〈 0.05]. ③ Therapeutic effects and side effects： The total significant effective rates in the combined treatment group and simple treatment group were 93% and 81% respectively. In the combined treatment group, 1 case suffered from palpitation, dizziness and agrypnia. In the simple treatment group, 1 case suffered from palpitation, dizziness and agrypnia, 1 case had itch of skin. All the above symptoms disappeared gradually after the transfusing speed was adjusted to be slower. No drug withdrawal occurred in the patients due to the adverse events. CONCLUSION： Cinepazide maleate combined with tanshinon can obviously improve the abnormalities of hemorrheologic indexes and blood lipids and nerve function in patients with acute cerebral infarction, and its curative effect is faster than that of simple cinepazide maleate treatment.

Effect of Rosiglitazone Maleate on Inflammation Following Cerebral Ischemia/Reperfusion in Rats

In order to evaluate the neuroprotective effect of Rosiglitazone Maleate (RSG) against brain ischemic injury, the effects of Rosiglitazone Maleate on the inflammation following cerebral ischemia/reperfusion were investigated. Focal cerebral ischemia was induced by the intraluminal thread for cerebral middle artery (MCA) occlusion. Rosiglitazone Maleate at concentrations of 0.5, 2 and 5 mg/kg was infused by intragastric gavage twice immediately and 2 h after MCA occlusion, respectively. The effects of Rosiglitazone Maleate on brain swelling, myeloperoxidase and inter- leukin-6 mRNA level in brain tissue after MCA occlusion and reperfusion were evaluated. The results showed that as compared with the model control group, RSG (0.5 mg/kg) had no significant influence on brain swelling (P>0.05), but 2 mg/kg and 5 mg/kg RSG could significantly alleviate brain swell- ing (P<0.05). All different doses of RSG could obviously reduce MPO activity in brain tissue after MCA occlusion and reperfusion in a dose-dependent manner. RSG (0.5 and 2 mg/kg) could decrease the expression levels of IL-6 mRNA in brain tissue after MCA occlusion and reperfusion to varying degrees (P<0.05) with the difference being significant between them. It was concluded that RSG could effectively ameliorate brain ischemic injury after 24 h MCA occlusion and inhibit the inflam- matory response after ischemia-reperfusion in this model.

Near-infrared chemical imaging for quantitative analysis of chlorpheniramine maleate and distribution homogeneity assessment in pharmaceutical formulations

Near infrared chemical imaging(NIR-CI)combines conventional near infrared(NIR)spectros-copy with chemical imaging,thus provides spectral and spatial information simult aneously.It could be utilized to visualize the spatial distribution of the ingredients in a sample.The data acquired using NIR CI instrument are hyperspectral data cube(hypercube)containing thousands of spectra.Chemometric methodologies are necessary to transform spectral information into chemical information.Partial least squares(PLS)method was performed to extract chemical information of chlorpheniramine maleate in pharmaceutical formulations.A series of samples which consisted of different CPM concentrations(w/w)were compressed and hypercube data were measured.The spectra extracted from the hypercube were used to establish the PLS model of CPM.The results of the model were R^(2)_(val)0.981,RMSEC 0.384%,RMSECV 0.483%,RMSEP 0.631%,indicating that this model was reliable.

Aqueous Diels-Alder Reactions of Cyclopentadicnc with Symmetric Diester of Fumarate or Maleate

Symmetric, diesters of cis- or trans- bicyclo[2,2,1]hept-5-ene-2,3-dicarboxylate were prepared by aqueous Diels-Alder reaction of cyclopentadiene with symmetric diester of fumarate or maleate.

One hundred and ninety-two weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or C

BACKGROUND Entecavir(ETV)is a potent and selective nucleotide analog with significant activity against hepatitis B virus(HBV).ETV maleate is a derivative compound of ETV and was reported to have an efficacy and safety profile that is comparable to ETV(Baraclude)when used in Chinese patients with chronic hepatitis B(CHB)in phase III clinical trials(Clinical Trials.gov number,NCT-01926288)at weeks 48,96,and 144.AIM To investigate the antiviral potency and safety of ETV maleate at week 192 in Chinese CHB patients predominantly genotyped B or C.METHODS In this double-blind study,we randomly assigned patients to receive 0.5 mg/d ETV(Group A)or ETV maleate(Group B)(ratio,1:1),each with a placebo tablet for 48 wk.Then,all patients received open-label treatment with 0.5 mg/d ETV maleate starting at week 49.The primary efficacy endpoint was the reduction in HBV DNA levels from baseline.Secondary endpoints included the proportion of patients with undetectable HBV DNA(<20 IU/m L),serologic response,serum alanine aminotransferase(ALT)normalization and development of resistance mutations.RESULTS Two hundred eighteen patients who were hepatitis B e antigen(HBe Ag)positive and 57 who were HBe Ag negative were analyzed and predominantly presented with genotype B(49.82%)or C(48.73%).For the HBe Ag-positive CHB patients,the mean HBV DNA level decrease(6.61 Log10 IU/m L vs 6.69 Log10 IU/m L,P>0.05),viral suppression with HBV DNA<20 IU/m L(83.33%vs 79.17%,P>0.05)and HBe Ag seroconversion(28.77%vs 20.00%,P>0.05)occurred similarly between Groups A and B at week 192.However,there was a significant difference in the proportion of patients with normal ALT levels(91.14%vs 78.38%,P<0.05).For the HBe Ag-negative CHB patients,no significant difference was found between Groups A and B at week 192 in terms of reductions in HBV DNA levels from baseline(6.05 Log10 IU/m L vs 6.03 Log10 IU/m L,P>0.05),percentages of patients who achieved undetectable HBV DNA(100%vs 100%,P>0.05)and rates of ALT normalization(95.65%vs 100.00%,P>0.05).Safety and adverse event profiles were similar between Groups A and B.Two HBe Ag-positive patients in Group A and 5 in Group B developed genotypic resistance to ETV.CONCLUSION Long-term ETV maleate treatment for up to 192 wk is effective and safe in Chinese CHB patients predominantly genotyped as B or C.

Square Wave Voltammetric Behavior of N,N-DiethyI-P-Nitroso Aniline an Indirect Method for Determination of Chlorpheniramin Maleate, Application of Pharmaceutical Formulations

The electrochemical behavior of N,N-diethyl-p-nitroso aniline was carried out using SWV （square wave voltammetric） at HMDE. A well defined reduction peak was observed at （-0.214） volt versus the reference electrode （Ag/AgC1/sat. KCI）, calibration curve was constructed in phosphate buffer （pH = 7.0）, the relationship is linear within the concentration range 1.283 × 10.5 M - 3.66 × 10.5 M with the correlation （R = 0.9923）. The serial addition ofCPM （chlorpheniramine maleate） leads to the decrease in the reduction current peak （Ip）, quantitatively, the plot of Alp （Ip - Ip） where, Ip： Peak current of N, N-diethyl-p-nitroso aniline alone, lp： peak current of N,N-diethyl-p-nitroso aniline in the presence of CPM, versus concentration is linear within the concentration range 0.984 × 10-6 M - 9.756 × 10-6 M, the correlation coefficient was 0.9954. The method was successfully applied to determine CPM in different types of pharmaceutical formulations, and compared with standard method from British Pharmacopeia [1].

A novel synthesis of fluvoxamine maleate

Fluvoxamine maleate is an excellent antidepressive drug. In the literatures, it was synthesized by the use of 4-（trifluoromethyl） aniline or 4-（trifluoromethyl） benzonitrile as starting materials and 5-methoxy-4＇-（trifluoromethyl-phenyl） valerophenone as a key intermediate. However, the methods in literatures have some disadvantages, such as the use of expensive materials, heavy pollution of environment, long reaction time and low yield of the product （only 30-40% overall yield）. We herein report an environmentally friendly synthetic method of fluvoxamine maleate, which used 4-（trifluoromethyl） benzoic acid and tetrahydrofuran as starting materials and FeCI3 as catalyst for the coupling of acid chloride with Grignard reagent. The fluvoxamine maleate was synthesized in 46% overall yield, through the oximation, etheration and salification of the intermediate successively.This method has some advantages, such as the use of commercially available materials, low cost, short production period （12-14 h）, high yield and light pollution.

Effect of Cinepazide Maleate Combined with Promethazine Hydrochloride in the Treatment of Emergency Vertigo

Objective:To explore the effect of cinepazide maleate combined with promethazine hydrochloride in the treatment of emergency vertigo.Methods:48 cases of emergency vertigo patients in our hospital from November 2017 to November 2019 were divided into experimental group(24 cases,treated with cinepazide maleate combined with promethazine hydrochloride)and control group (24 cases,treated with cinepazide maleate).The clinical efficacy,symptom relief time,adverse reactions and quality of life were compared.Results:The total effective rate of the experimental group(95.83%,23/24)was higher than that of the control group(75.00%),The remission time of nausea and vomiting(1.75±0.22)d,vertigo(3.54±0.63)d,deafiiess and tinnitus(3.47±0.58)d,night sweats(3.05±0.33)d in the experimental group were shorter than those in the control group,P<0.05;the incidence of adverse reactions in the experimental group(8.33%,2/24)was lower than that in the control group(33.33%),The scores of social function,material life attitude,physical health and psychological function in the experimental group were 59.14±7.23,54.05±8.04,53.58±0.86 and 60.11±8.44 respectively,P<0.05.Conclusion:In the process of clinical treatment of emergency vertigo patients,the combined application of cinepazide maleate and promethazine hydrochloride has definite curative effect,can relieve clinical symptoms in a short time,has less adverse reactions,and improves the quality of life of patients to a certain extent,which is worthy of promotion.

Irsogladine maleate and rabeprazole in non-erosive reflux disease: A double-blind, placebo-controlled study

AIM:To evaluate the efficacy of adding irsogladine maleate(IM) to proton-pump inhibitor(PPI) therapy in non-erosive reflux disease(NERD) treatment.METHODS:One hundred patients with NERD were recruited and randomized to receive rabeprazole plus IM(group I) or rabeprazole plus placebo(group P).The efficacy of the treatment was assessed using the Frequency Scale for the Symptoms of Gastroesophageal Reflux Disease(FSSG) and the short form(SF)-36 quality of life questionnaires after four weeks of treatment.We also assessed whether patients with NERD with minimal changes(grade M) had different responses to the therapies compared with patients who did not have minimal changes(grade N).RESULTS:Group I and group P showed significant improvements in their FSSG scores after the treatment(from 17.9 ± 7.9 to 9.0 ± 7.6, and from 17.7 ± 7.3 to 11.2 ± 7.9, respectively, P = 0.0001), but there was no statistically significant difference between the FSSG scores in group I and those in group P.Subgroup analysis showed that significant improvements in the FSSG scores occurred in the patients in group I who had NERD grade N(modified Los Angeles classification)(7.8 ± 7.4 vs 12.5 ± 9.8, P = 0.041).The SF-36 scores for patients with NERD grade N who had received IM and rabeprazole were significantly improved in relation to their vitality and mental health scores.CONCLUSION:The addition of IM to rabeprazole significantly improves gastroesophageal reflux diseasesymptoms and the quality of the lives of patients with NERD grade N.

Sonochemical Synthesis of Maleated Rosin

The cycloaddition reaction of rosin and maleic anhydride under ultrasonic irradiation has been investigated. The results show that both isomerization and Diels-Alder cycloaddition reactions were accelerated remarkably. The sonochemical reaction reached equilibrium in 5-10 min at 110℃, comparing with regular synthesis of 4-5 h over 180℃.

治疗血小板减少症新药——马来酸阿凡泊帕(avatrombopag maleate)

马来酸阿凡泊帕(avatrombopag maleate)是血小板生成素受体激动药,最早由日本安斯泰来制药集团研制,几经授权,最后由美国Dova制药公司的子公司AkaRx制药公司完成新药研制,向美国食品药品管理局(FDA)提出新药上市申请,于2018年5月21日获准上市,商品名为Doptelet,用于患有血小板减少症并拟接受医疗或牙科手术的成人慢性肝病(CLD)患者。该文对马来酸阿凡泊帕的非临床和临床药理毒理学、临床研究、不良反应、适应证、剂量与用法、用药注意事项及知识产权状态和国内外研究进展等进行介绍。

Synthesis and Characterization of a Cobalt Complex with Maleate and Pyridine

A new polymeric cobalt complex [Co(-male)(py)(H2O)]n (male = maleate; py = pyridine) 1 was prepared by cobalt chloride hexahydrate with disodium maleate and pyridine in an alcohol-aqueous solution. Single-crystal X-ray analysis has revealed that 1 crystallizes in the orthor- hombic system, space group Pnma with a = 18.001(1), b = 7.6001(6), c = 7.4731(6) ? V = 1022.4(1) 3, Z = 4, C9H9CoNO5, Mr = 270.10, Dc = 1.755 g/cm3, F(000) = 548, m(MoK? = 1.683 mm-1, S = 1.002, the final R = 0.0280 and wR = 0.0746 for 883 observed reflections with I > 2s(I). The structure analysis shows an approximate octahedral coordination environment of metal center. The Co(II) ions are bridged by maleic anions in a rare tetradentate coordination fashion with a syn-anti coplanar con- formation of the carboxyl group, forming a two-dimensional corrugated 2-D structure which is further attached into a three-dimensional framework via non-classical CH…O interactions between adjacent layers.

Conventional Radical and RAFT Alternating Copolymerizations of Hydroxyalkyl Vinyl Ethers and Dialkyl Maleates

The alternating copolymerization of hydroxyalkyl vinyl ethers and dialkyl maleates is investigated by conventional radical polymerization and reversible addition-fragmentation chain transfer polymerization(RAFT).The influence of comonomer structure,comonomer feeding ratios,and monomer concentrations on the copolymerization and the copolymer structure have been investigated systematically.With 2-hydroxyethyl vinyl ether(HEVE)and dimethyl maleates(DMM)as comonomers,a well-defined alternating copolymer is prepared with M_(n)=3400 and M_(w)/M_(n)=1.93 up to 71.6% monomer.The alternating sequential chain structure of the copolymers has been proved by both NMR and matrixassisted laser desorption/ionization time-of-flight mass spectrometry(MALDI-TOF MS).The experimental reactivity ratios and theoretical calculated highest occupied molecular orbital and the lowest unoccupied molecular orbital of vinyl ethers and alkyl maleates support that these monomer pairs have tendency to form alternating copolymers.With 2-cyanopropan-2-yl N-methyl-N-(pyridin-4-yl)carbamodithioate as the RAFT agent,the molecular weight of HEVE and DMM copolymer increases with the monomer conversion,demonstrating a controlled radical polymerization feature with well-controlled molecular weight and relatively narrower molecular weight distribution.With alternating copolymer of HEVE and DMM as macro-CTA(M_(n)=5200 and M_(w)/M_(n)=1.46),both the chain extension with HEVE and DMM(M_(n)=10400 and M_(w)/M_(n)=1.72)and block copolymerization with vinyl acetate have been successfully achieved(M_(n)=8500 and M_(w)/M_(n)=1.52).

马来酸麦角新碱联合卡前列素氨丁三醇对宫缩乏力性产后出血的防治效果

目的探究马来酸麦角新碱联合卡前列素氨丁三醇在宫缩乏力性产后出血防治中的应用效果,以期为临床提供一种更安全有效的治疗方案。方法收集2020年3月至2022年3月在本院就诊的自然分娩产妇82例,采用随机数字表法分组,即对照组、观察组,均41例。对照组予以缩宫素注射液,观察组在对照组的基础上增加马来酸麦角新碱联合卡前列素氨丁三醇。统计两组产妇产后出血情况、宫底情况及不良反应等。结果观察组产妇产后2h、12h、24h出血量、产后出血发生率、宫底高度、恶露持续时间、宫腔积血发生率均低于对照组(P<0.05);两组不良反应发生率比较,P>0.05。结论来酸麦角新碱联合卡前列素氨丁三醇在宫缩乏力性产后出血防治中具有显著的应用优势,能有效降低产后出血发生率和出血量,减少宫底高度和恶露持续时间,且安全性高。

马来酸依那普利叶酸片治疗H型高血压的效果及对脑卒中的预防作用

目的:分析马来酸依那普利叶酸片治疗H型高血压的效果及对脑卒中的预防作用。方法:选取2013年4月—2020年6月梧州市红十字会医院心内科治疗的H型高血压患者201例为研究对象,随机分为观察组(101例)和对照组(100例)。对照组口服厄贝沙坦片治疗,观察组口服马来酸依那普利叶酸片治疗。比较两组血压、血清同型半胱氨酸(Hcy)、不良反应发生情况、脑卒中发生率。结果:治疗前后,两组收缩压(SBP)、舒张压(DBP)水平比较,差异无统计学意义(P>0.05);治疗后,两组SBP、DBP水平低于治疗前,差异有统计学意义(P<0.05)。治疗前,两组Hcy水平比较,差异无统计学意义(P>0.05);治疗后,两组Hcy水平低于治疗前,观察组低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05);观察组脑卒中发生率低于对照组,差异有统计学意义(P=0.049)。结论:马来酸依那普利叶酸片治疗H型高血压患者可有效降低血压、Hcy水平及脑卒中发生率。

高效液相色谱法测定复方吲哚美辛酊中马来酸氯苯那敏的含量

目的:采用Waters C18柱(5μm,4.6*250 mm),以磷酸盐缓冲液(取磷酸二氢铵11.5 g,加适量水使其溶解,加磷酸1 m L,用水稀释至1000 m L)-乙腈(80∶20)为流动相。流速1.0 mL/min,检测波长为262,柱温为30℃条件下,建立高效液相色谱(HPLC)测定马来酸氯苯那敏的方法。结果表明,马来酸氯苯那敏的进样量在20.272~141.904μg范围内有良好的线性关系,回归方程y=0.1153x-0.0162(R=0.9999),方法回收率为99.19%~101.68%之间,RSD为0.9%。6批样品的马来酸氯苯那敏含量在98.97%~101.58%之间;结论:此方法专属性强,精密度稳定性良好,准确度较高,可用于该制剂中马来酸氯苯那敏的含量测定。

CoO_(x)引入Pd/HAC催化剂增强乙炔双羰化反应活性

使用[Pd_(2)(μ-CO)_(2)Cl_(4)]_(2)−原位生成Pd纳米粒子和等体积浸渍法,制备了一系列CoO_(x)-Pd/HAC催化剂,并考察了其在乙炔二羰基化反应中的反应活性.结果表明,3%Co-Pd/HAC催化剂在乙炔二羰基化反应中具有最佳活性(乙炔转化率75.4%,马来酸二甲酯选择性86.2%).采用X射线衍射(XRD)、氢温度程序还原(H2-TPR)、透射电镜(TEM)等手段对催化剂进行了表征.适量金属钴氧化物的加入可以驱动钯纳米颗粒表面的电子迁移,产生更多的高价钯物种,增强CO的吸附能力,驱动羰基化反应步骤Pd^(δ+)↔Pd^(0)循环过程,从而提高乙炔双羰基化反应活性.经过7个循环实验,Co-Pd/HAC催化剂有微弱失活现象,但对丁烯二酸二甲酯的选择性没有显著影响.

Self-assembly of Two Novel Supramolecular Frameworks Based on Flexible Oligo-a-Pyridylamino Ligands and Copper（Ⅱ） Maleate

Two novel supramolecular complexes, [Cu（bopapa）（mal）]·H2O·CH3OH （1） and {[Cu（bopapap）]（Hmal）2}·2H2O （2） [bpapa = bis-[6-（2-pyridylamino）pyrid-2-yl]amine, bpapap = 2,6-bis-[6-（pyrid-2-ylamino）pyrid-2-ylamino]- pyridine, mal=maleate dianion] were rationally designed and synthesized based on flexible multidentate ligands and copper（Ⅱ） maleate. Complexes 1 and 2 were all characterized by elemental analysis, spectroscopic techniques, thermal analysis and single crystal X-ray diffraction analysis. Complex 1 is of an infinite 3-D supramolecular framework constructed by 2-D sheets to contain 1-D helical chains formed by intermolecular hydrogen bond inter- actions between the non-coordinated oxygen atoms from maleate and nitrogen atoms from amino groups of bpapa. Complex 2 also takes a 3-D supramolecular structure, which is built from 2-D rhombic sheets produced by sequential dimer units. Interestingly, three pairs of symmetrical hydrogen bonds generate these dimer units.

马来酸曲美布汀联合谷维素治疗肠功能紊乱的疗效分析

目的 分析马来酸曲美布汀联合谷维素治疗肠功能紊乱的疗效。方法 非随机选取2022年8月—2023年9月寿光市人民医院收治的70例肠功能紊乱患者为研究对象,并根据治疗方法不同分为常规组与研究组,各35例。将马来酸曲美布汀应用于常规组,研究组以常规组为基础,给予谷维素治疗,分析对比两组治疗效果、肠道改善情况、胃肠功能指标、炎症因子水平。结果 研究组治疗总有效率为97.14%(34/35),高于常规组的82.86%(29/35),差异有统计学意义(χ^(2)=3.968,P<0.05)。研究组腹痛次数、大便次数、便血次数、肠鸣音次数均少于常规组,差异有统计学意义(P均<0.05)。治疗后研究组血清胃泌素和促胃动素水平均高于常规组,差异有统计学意义(P均<0.05)。治疗后研究组炎症因子水平均低于常规组,差异有统计学意义(P均<0.05)。结论 肠功能紊乱患者采取马来酸曲美布汀联合谷维素治疗可提高治疗有效率,改善胃肠功能、减轻炎症反应。